Form 4: Catalyst Pharma Officer Acquires Shares Post-RSU Vesting

Catalyst Pharmaceuticals' Chief Operating & Scientific Officer, Steve Miller, acquired 14,000 shares of common stock following the vesting and delivery of restricted stock units.

Summary

• Steve Miller, Chief Operating & Scientific Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported a transaction on December 29, 2025.
• Miller acquired 14,000 shares of common stock, par value $0.001 per share, through the vesting and delivery of Restricted Stock Units (RSUs).
• Following this transaction, Miller directly beneficially owns 1,093,803 shares of common stock.
• The RSUs vested in three equal tranches: December 27, 2023, December 27, 2024, and December 27, 2025.
• The final tranche of 14,000 shares was delivered on December 29, 2025, within sixty days of vesting.
• Miller continues to hold 1,471,649 derivative securities (RSUs) beneficially owned following this reported transaction.

Sentiment

Score: 6

Explanation: The filing reports a routine, pre-scheduled vesting and delivery of equity compensation to a key executive. While it shows continued insider ownership, it doesn't indicate new strategic moves or significant financial performance changes, hence a neutral-positive score reflecting a standard, non-eventful transaction.

Positives

• Increased direct ownership of common stock by a key executive, Steve Miller, indicating continued alignment with shareholder interests.
• The transaction is a result of a pre-scheduled vesting of Restricted Stock Units, reflecting a planned compensation event.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to executive compensation. It reflects the company's ongoing compensation structure for its officers, aligning their interests with long-term company performance through equity awards, a common practice in the biotechnology and pharmaceutical sectors.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a common practice across the biotechnology and pharmaceutical industries, aligning executive incentives with long-term shareholder value.
• The vesting schedule in tranches over several years is standard for equity compensation, promoting retention and sustained performance, similar to practices observed at comparable companies in the biopharma space.

Stakeholder Impact

• Shareholders: The increase in direct common stock ownership by a key officer may be viewed positively as it aligns management's interests with shareholders.
• Employees: This transaction reflects the company's executive compensation practices, which can influence broader employee compensation strategies and morale.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled vesting and delivery of Restricted Stock Units to a key executive. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transaction is an expected part of executive compensation and does not signal a significant shift in the company's outlook or valuation, thus a 'hold' recommendation is appropriate.

Keywords

Catalyst Pharmaceuticals, CPRX, Steve Miller, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Common Stock, Beneficial Ownership, Officer Compensation